Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 3Recruiting 2Enrolling by invitation 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 470Neoplasms 328Colorectal Neoplasms 237Carcinoma, Non-Small-Cell Lung 232Lung Neoplasms 202Prostatic Neoplasms 181Carcinoma, Hepatocellular 173Stomach Neoplasms 138Pancreatic Neoplasms 124Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 104Multiple Myeloma 92Recurrence 87Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 78Neoplasm Metastasis 76Ovarian Neoplasms 74Colonic Neoplasms 69Brain Neoplasms 68Triple Negative Breast Neoplasms 66Esophageal Neoplasms 66Glioblastoma 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Motor Activity 55Small Cell Lung Carcinoma 54Disease 54Hematologic Neoplasms 53Glioma 47

Interventions

telitacicept 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Neuromuscular Diseases × Clear all
NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡